Literature DB >> 21731196

Matrix metalloproteinases and their inhibitors: correlation with invasion and metastasis in oral cancer.

Ragini D Singh, N Haridas, Jayendra B Patel, Franky D Shah, Shilin N Shukla, Pankaj M Shah, Prabhudas S Patel.   

Abstract

Matrix metalloproteinases (MMPs) have been implicated in invasion and metastasis of various malignancies. The study evaluated a comprehensive profile of MMP-2 and MMP-9 and their inhibitors, tissue inhibitor of metalloproteinases-2 (TIMP-2) and tissue inhibitor of metalloproteinases-1 (TIMP-1), respectively in 50 controls and 75 patients with oral squamous cell carcinoma (OSCC). Blood samples from controls and patients as well as malignant and adjacent normal tissues from the patients were collected. The study examined pro, active and total forms of MMP-2 and MMP-9 using zymography. Enzyme-linked immunoassay (ELISA) and reverse transcription polymerase chain reaction were carried out to evaluate protein levels and mRNA expression; respectively, for the MMPs and TIMPs. Plasma pro, active and total MMP-2, MMP-9 as well as TIMP-1 and TIMP-2 levels were significantly higher in oral cancer patients as compared to the controls. mRNA expression of the MMPs and TIMPs was significantly higher in malignant tissues as compared to adjacent normal tissues. A significant positive correlation was observed between levels of proMMP-9 and active MMP-9 with differentiation, stage and infiltration. ProMMP-2 and active MMP-2 exhibited significant positive correlation with differentiation and lymph node involvement. The multivariate analysis of ELISA results revealed a significant positive correlation between MMP-2, TIMP-1 and TIMP-2 levels with lymph node involvement, stage and differentiation. The receiver operating characteristic curve (ROC) analysis showed that the levels of MMPs and TIMPs have significant discriminatory efficacy to differentiate between controls and patients. The results indicate that MMP-2, MMP-9, TIMP-1 and TIMP-2 have significant clinical usefulness for oral cancer patients. Zymographic analysis is a simple, cost effective, rapid and sensitive alternative assay.

Entities:  

Keywords:  Invasion; MMPs; Metastasis; Oral cancer; TIMPs; Zymography

Year:  2010        PMID: 21731196      PMCID: PMC3001841          DOI: 10.1007/s12291-010-0060-8

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  30 in total

1.  Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in head and neck squamous cell carcinoma.

Authors:  S J Charous; G P Stricklin; L B Nanney; J L Netterville; B B Burkey
Journal:  Ann Otol Rhinol Laryngol       Date:  1997-04       Impact factor: 1.547

2.  Active-MMP2 in cancer cell nests of oral cancer patients: correlation with lymph node metastasis.

Authors:  H Kawamata; D Uchida; H Hamano; T Kimura-Yanagawa; K I Nakashiro; S Hino; F Omotehara; H Yoshida; M Sato
Journal:  Int J Oncol       Date:  1998-10       Impact factor: 5.650

3.  Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma.

Authors:  F Riedel; K Götte; J Schwalb; K Hörmann
Journal:  Anticancer Res       Date:  2000 Sep-Oct       Impact factor: 2.480

4.  Circulating 92-kilodalton matrix metalloproteinase (MMP-9) activity is enhanced in the euglobulin plasma fraction of head and neck squamous cell carcinoma.

Authors:  Stella M Ranuncolo; Elena Matos; Dora Loria; Marta Vilensky; Rodrigo Rojo; Elisa Bal de Kier Joffé; Lydia Inés Puricelli
Journal:  Cancer       Date:  2002-03-01       Impact factor: 6.860

5.  Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis.

Authors:  S Kurahara; M Shinohara; T Ikebe; S Nakamura; M Beppu; A Hiraki; H Takeuchi; K Shirasuna
Journal:  Head Neck       Date:  1999-10       Impact factor: 3.147

6.  Matrix metalloproteinases: biologic activity and clinical implications.

Authors:  A R Nelson; B Fingleton; M L Rothenberg; L M Matrisian
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

7.  Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion.

Authors:  P O-Charoenrat; P Rhys-Evans; H Modjtahedi; W Court; G Box; S Eccles
Journal:  Int J Cancer       Date:  2000-05-01       Impact factor: 7.396

8.  Tumor marker potential of serum matrix metalloproteinases in patients with head and neck cancer.

Authors:  C Kuropkat; S Plehn; U Herz; A A Dünne; H Renz; J A Werner
Journal:  Anticancer Res       Date:  2002 Jul-Aug       Impact factor: 2.480

9.  Cost-effectiveness of oral cancer screening: results from a cluster randomized controlled trial in India.

Authors:  Sujha Subramanian; Rengaswamy Sankaranarayanan; Bela Bapat; Thara Somanathan; Gigi Thomas; Babu Mathew; Jissa Vinoda; Kunnambath Ramadas
Journal:  Bull World Health Organ       Date:  2009-03       Impact factor: 9.408

10.  Analysis of expression of matrix metalloproteinases-2 and -9 in hypopharyngeal squamous cell carcinoma by in situ hybridization.

Authors:  Y Miyajima; R Nakano; M Morimatsu
Journal:  Ann Otol Rhinol Laryngol       Date:  1995-09       Impact factor: 1.547

View more
  13 in total

Review 1.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

2.  Human aqueous humor levels of transforming growth factor-β2: Association with matrix metalloproteinases/tissue inhibitors of matrix metalloproteinases.

Authors:  Yan Jia; Yu Yue; Dan-Ning Hu; Ji-Li Chen; Ji-Bo Zhou
Journal:  Biomed Rep       Date:  2017-10-20

Review 3.  Glycosylation: a hallmark of cancer?

Authors:  Bhairavi N Vajaria; Prabhudas S Patel
Journal:  Glycoconj J       Date:  2016-12-14       Impact factor: 2.916

4.  A review on salivary genomics and proteomics biomarkers in oral cancer.

Authors:  Franky D Shah; Rasheedunnisa Begum; Bhairavi N Vajaria; Kinjal R Patel; Jayendra B Patel; Shilin N Shukla; Prabhudas S Patel
Journal:  Indian J Clin Biochem       Date:  2011-08-09

5.  High expression of matrix metalloproteinase-9 indicates poor prognosis in human hilar cholangiocarcinoma.

Authors:  Qi Sun; Chuanzong Zhao; Leizhou Xia; Zhaobin He; Zhihua Lu; Chuan Liu; Ming Jia; Jiayong Wang; Jun Niu
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

6.  The Contribution of Matrix Metalloproteinase-8 Promoter Polymorphism to Oral Cancer Susceptibility.

Authors:  Yi-Wen Hung; Chia-Wen Tsai; Cheng-Nan Wu; Liang-Chun Shih; Yen-Yu Chen; Yen-Fang Liu; Huey-Shan Hung; Ming-Yi Shen; Wen-Shin Chang; DA-Tian Bau
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

7.  Annexin A1, A2, A4 and A5 play important roles in breast cancer, pancreatic cancer and laryngeal carcinoma, alone and/or synergistically.

Authors:  Shishan Deng; Jianguo Wang; Lingmi Hou; Jinsui Li; Guo Chen; Baoqian Jing; Xiaoming Zhang; Zhengwei Yang
Journal:  Oncol Lett       Date:  2012-10-09       Impact factor: 2.967

8.  The impact of TGF-β1 on the mRNA expression of TβR I, TβR II, Smad4 and the invasiveness of the JEG-3 placental choriocarcinoma cell line.

Authors:  Yuhong Li; Qian Xu; Zhuo Zhang; Shaochen Liu; Changhua Shi; Yusi Tan
Journal:  Oncol Lett       Date:  2012-09-11       Impact factor: 2.967

9.  Osteopontin expression in co-cultures of human squamous cell carcinoma-derived cells and osteoblastic cells and its effects on the neoplastic cell phenotype and osteoclastic activation.

Authors:  Lucas Novaes Teixeira; Larissa Moreira Spinola de Castro Raucci; Gabriela Caroline Alonso; Ricardo Della Coletta; Adalberto Luiz Rosa; Paulo Tambasco de Oliveira
Journal:  Tumour Biol       Date:  2016-06-16

Review 10.  Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma.

Authors:  Suvi-Tuuli Vilen; Tuula Salo; Timo Sorsa; Pia Nyberg
Journal:  ScientificWorldJournal       Date:  2013-01-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.